Ashwagandha: Is It Safe? Part 1: A Regulatory Review.

Area of Science:

• Pharmacology and Toxicology
• Regulatory Science
• Herbal Medicine Research

Background:

• Ashwagandha (Withania somnifera (L.) Dunal, AS) has faced increasing scrutiny from EU regulators concerning its safety for food supplement use.
• This scrutiny has led to a recommendation for an Article 8 procedure under Regulation (EC) No. 1925/2006, potentially banning its use in the EU.
• The regulatory landscape for AS is complex and varies significantly across major global markets.

Purpose of the Study:

• To provide a comprehensive overview of the current regulatory status of ashwagandha (AS) in key international markets.
• To analyze the factors contributing to the increased regulatory scrutiny of AS, particularly within the European Union.
• To inform stakeholders about potential regulatory actions and their implications for the global food supplement industry.

Main Methods:

• Systematic review of regulatory documents and scientific literature pertaining to ashwagandha safety and regulation.
• Comparative analysis of regulatory frameworks governing herbal ingredients in major global marketplaces.
• Examination of the EU's regulatory procedures, including Regulation (EC) No. 1925/2006 and the Article 8 procedure.

Main Results:

• The European Union is considering a ban on ashwagandha in food supplements following safety concerns and a recommendation for an Article 8 procedure.
• Regulatory approaches to ashwagandha differ significantly across major markets, with varying levels of oversight and restrictions.
• The review highlights the need for harmonized international standards for assessing the safety and efficacy of herbal ingredients.

Conclusions:

• The potential EU ban on ashwagandha underscores the critical importance of robust safety assessments for botanicals used in food supplements.
• Understanding diverse global regulatory landscapes is crucial for businesses involved in the international trade of ashwagandha.
• Further research and transparent communication are needed to address regulatory concerns and ensure the safe use of ashwagandha worldwide.